Cost and Exposure Divide the Two ETFs
The Invesco Nasdaq Biotechnology ETF, known as IBBQ, has an expense ratio of 0.19%, which is considerably lower than the 0.40% charged by the iShares Global Healthcare ETF, or IXJ. This makes IBBQ a more affordable choice for investors looking to reduce fees. In terms of income generation, IXJ provides a higher yield of 1.50% for the past year, nearly double the 0.80% dividend yield from IBBQ.
The iShares fund, IXJ, spreads its investments across 110 companies in the pharmaceutical, biotechnology, and medical device industries. These companies are located in both developed and emerging markets. On the other hand, IBBQ is focused on 251 biotech and pharmaceutical firms listed on the Nasdaq. A major difference is that IBBQ allocates 38% of its holdings to small-cap stocks, while IXJ only includes 1% small-cap exposure.
IBBQ’s Edge in Growth, IXJ’s in Stability
Over the course of the past year, IBBQ has outperformed IXJ with a return of 15.3% compared to IXJ’s 2%. In a three-year span, IBBQ achieved 18% returns versus IXJ’s 6.6%. Looking forward to 2026, these numbers suggest that IBBQ might be a better pick for investors willing to take on more risk in exchange for stronger potential growth.
The iShares fund includes major holdings such as Eli Lilly with a 10.9% allocation, Johnson & Johnson at 7%, and AbbVie at 5.1%. In contrast, IBBQ features Vertex Pharmaceuticals as its top holding at 8.1%, followed by Amgen at 7.9% and Gilead Sciences at 6.9%. The emphasis on mid- and small-cap companies in IBBQ adds more volatility to its portfolio.
While IXJ offers lower volatility and a consistent 1.50% yield, IBBQ shows better returns over a five-year period, with 5.7% compared to IXJ’s 4.9%. Choosing between the two comes down to whether an investor prioritizes regular income and stability or is focused on potential long-term growth. IBBQ remains primarily focused on U.S. stocks, but it does have a 6% allocation to non-U.S. companies, emphasizing innovation in the biotech sector.
Notably, the Motley Fool's top 10 stock picks for 2026 do not include IXJ. This might indicate a preference among investors for individual stocks over ETFs for strong growth. However, IBBQ's recent performance and momentum could still make it a compelling option for those looking to invest in the healthcare sector through an ETF.
To summarize, investors choosing between IXJ and IBBQ should consider their financial goals. Those seeking regular income and a more stable return might favor IXJ, while IBBQ could be better suited for those willing to take on more risk in pursuit of higher returns. Both ETFs provide access to different parts of the healthcare market, and the decision ultimately depends on individual investment priorities.
For additional guidance on ETF investing and to understand which healthcare ETF might align best with your portfolio, it is recommended to consult a detailed analysis or reach out to a financial advisor. Whether it's through an ETF or individual stocks, the healthcare sector offers numerous opportunities for investors, depending on their tolerance for risk and interest in long-term growth.
Understanding the nuances between IXJ and IBBQ allows investors to make informed choices. By evaluating factors such as cost, yield, and long-term performance, individuals can determine which ETF better fits their investment strategy. The healthcare sector continues to evolve, and selecting the right vehicle for investment can help capture its potential while aligning with personal financial objectives.